-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $415

Benzinga·08/01/2025 14:58:02
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $390 to $415.